Ekso Bionics Holdings, Inc Announces Director Changes
December 09, 2022 at 06:10 am EST
Share
On December 8, 2022, effective immediately, the Board of Directors of Ekso Bionics Holdings, Inc. appointed Scott G. Davis to serve as a director of the Company, with Mr. Davis' term to expire as of 2023 Annual Meeting of Stockholders. Mr. Davis was recently appointed to serve as the Company's Chief Executive Officer, prior to which he served as the Company's President and Chief Operating Officer. Mr. Davis' biography was included in the proxy statement for the Company's 2022 Annual Meeting of Stockholders filed with the SEC on April 29, 2022 and is incorporated herein by reference.
Ekso Bionics Holdings, Inc. designs, develops, and markets exoskeleton products. Its exoskeleton technology serves multiple markets and can be utilized both by able-bodied persons and persons with physical disabilities or impairments. Its products include EksoNR, which is a wearable robotic exoskeleton specifically designed to be used in a rehabilitation setting; Ekso Indego Therapy is a modular, adjustable, lightweight, lower-limb powered exoskeleton; Ekso Indego Personal is a lightweight powered lower limb orthosis; Ekso Nomad is a power Knee Ankle Foot Orthosis, and Ekso EVO is a wearable upper body exoskeleton. The Company enables individuals with neurological conditions affecting gait, including acquired brain injury (ABI) and spinal cord injury (SCI), to rehabilitate and to walk again; assist individuals with a range of upper extremity impairments and allow industrial workers to perform difficult repetitive work for extended periods. Its segments include EksoHealth and EksoWorks.
EKSO BIONICS HOLDINGS, INC. 
